XOMAO Key Statistics, Chart & Performance
The current stock price of XOMAO is 25.355 USD. In the past month the price decreased by -0.33%. In the past year, price increased by 0.59%.
XOMAO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About XOMAO
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047200
XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ
What does XOMA ROYALTY CORP - XOMA 8 3/8 PERP do?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
What is the current price of XOMAO stock?
The current stock price of XOMAO is 25.355 USD. The price increased by 0.24% in the last trading session.
What is the dividend status of XOMA ROYALTY CORP - XOMA 8 3/8 PERP?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a dividend yield of 8.28%. The yearly dividend amount is currently 0.47.
What is the ChartMill rating of XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock?
XOMAO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for XOMAO stock?
The PE ratio for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 33.81. This is based on the reported non-GAAP earnings per share of 0.75 and the current share price of 25.355 USD.
What is XOMA ROYALTY CORP - XOMA 8 3/8 PERP worth?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a market capitalization of 313.89M USD. This makes XOMAO a Small Cap stock.
What is the next earnings date for XOMAO stock?
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) will report earnings on 2026-03-16, before the market open.
XOMAO Technical Analysis
XOMAO Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to XOMAO. While XOMAO is still in line with the averages on profitability rating, there are concerns on its financial health.
XOMAO Financial Highlights
Over the last trailing twelve months XOMAO reported a non-GAAP Earnings per Share(EPS) of 0.75. The EPS increased by 135.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.96% | ||
| ROA | 3.75% | ||
| ROE | 9.14% | ||
| Debt/Equity | 0.87 |
XOMAO Forecast & Estimates
10 analysts have analysed XOMAO and the average price target is 66.31 USD. This implies a price increase of 161.52% is expected in the next year compared to the current price of 25.355.
For the next year, analysts expect an EPS growth of 153.97% and a revenue growth 73.62% for XOMAO